How The GCS Project Started
GYN Carcinosarcoma (GCS) is also known as MMMT or malignant mixed Mullein tumor – but that is an older term. The cancer can start in the ovary or the uterus or the fallopian tubes. Regardless of the origin, it is a rare and highly aggressive form of cancer and represents 1-2% of ovarian cancers and 3-4% of uterine cancers.
Unfortunately, the tumor has a lower rate of response to standard chemotherapy and a higher rate of recurrence which makes it difficult to control.
Limited research has been directed to this cancer and perhaps that is why GCS is treated like either ovarian or uterine cancer. Maybe this is the right approach, but maybe it is the wrong direction. It doesn’t seem to be working. We need to find out why.
Carcinosarcoma is a Rare Cancer
- Less than 1,000 women each year are diagnosed with GCS compared to over 240,000 women a year diagnosed with breast cancer and over 240,000 men and women diagnosed with lung cancer.
- Because GCS is rare, it is at the bottom of the pile for research dollars. High prevalence cancers such as lung and breast receive most of the research dollars which makes sense unless you have a rare cancer.
- But that’s the way it is, so I decided to raise the funds needed to cure this rare cancer.
Why Massachusetts General Cancer Center?
- As a leading cancer center, Massachusetts General Hospital (MGH) sees a disproportionately higher number of patients with GCS due to its exceptional care and research programs.
- At present, 10% of Dr. Birrer’s patients have GCS.
- Dr. Michael Birrer and his brilliant team at MGH have agreed to provide the brainpower to establish for the first time a full understanding of this rare tumor. The data generated is most likely to form the basis of a more rational and targeted therapeutic approach to GCS and help improve the lives of patients living with this cancer.
The Research Has Begun …
Thanks to generous donations from my family. But more research dollars are needed to support this important project. This fund is unique in that ALL donations will be targeted to a restricted fund for GCS Research. There is no other research fund dedicated to this cause. Let’s support Dr. Birrer and his team at MGH and find a cure.